10,628 reports of this reaction
5.2% of all PALBOCICLIB reports
#3 most reported adverse reaction
NEOPLASM PROGRESSION is the #3 most commonly reported adverse reaction for PALBOCICLIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 10,628 FDA adverse event reports linking PALBOCICLIB to NEOPLASM PROGRESSION. This represents approximately 5.2% of all 205,909 adverse event reports for this drug.
PALBOCICLIB has an overall safety score of 78 out of 100. Patients taking PALBOCICLIB who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is moderately reported among PALBOCICLIB users, representing a notable but not dominant share of adverse events.
In addition to neoplasm progression, the following adverse reactions have been reported for PALBOCICLIB:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 10,628 FDA reports for PALBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 5.2% of all adverse event reports for PALBOCICLIB, making it one of the most commonly reported side effect.
If you experience neoplasm progression while taking PALBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.